Cargando…

Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells

The CDH1 gene, encoding the cell adhesion protein E-cadherin, is one of the most frequently mutated genes in gastric cancer and inactivating germline CDH1 mutations are responsible for hereditary diffuse gastric cancer syndrome (HDGC). Using cell viability assays, we identified that breast (MCF10A)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bougen-Zhukov, Nicola, Nouri, Yasmin, Godwin, Tanis, Taylor, Megan, Hakkaart, Christopher, Single, Andrew, Brew, Tom, Permina, Elizabeth, Chen, Augustine, Black, Michael A., Guilford, Parry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769709/ https://www.ncbi.nlm.nih.gov/pubmed/31540244 http://dx.doi.org/10.3390/cancers11091359

Ejemplares similares

Loss of E-Cadherin Leads to Druggable Vulnerabilities in Sphingolipid Metabolism and Vesicle Trafficking
por: Brew, Tom, et al.
Publicado: (2021)

E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function
por: Godwin, Tanis D., et al.
Publicado: (2018)

E-Cadherin-Deficient Epithelial Cells Are Sensitive to HDAC Inhibitors
por: Decourtye-Espiard, Lyvianne, et al.
Publicado: (2021)

E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib
por: Bougen-Zhukov, Nicola, et al.
Publicado: (2022)

A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells
por: Beetham, Henry, et al.
Publicado: (2019)

E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition
por: Chen, Augustine, et al.
Publicado: (2014)

E-cadherin signal sequence disruption: a novel mechanism underlying hereditary cancer
por: Figueiredo, Joana, et al.
Publicado: (2018)

Cohesin mutations are synthetic lethal with stimulation of WNT signaling
por: Chin, Chue Vin, et al.
Publicado: (2020)

Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality
por: Benfatto, Salvatore, et al.
Publicado: (2021)

Identifying collateral and synthetic lethal vulnerabilities within the DNA-damage response
por: Pinoli, Pietro, et al.
Publicado: (2021)

STAG1 vulnerabilities for exploiting cohesin synthetic lethality in STAG2-deficient cancers
por: van der Lelij, Petra, et al.
Publicado: (2020)

Viral protein engagement of GBF1 induces host cell vulnerability through synthetic lethality
por: Navare, Arti T, et al.
Publicado: (2020)

Viral protein engagement of GBF1 induces host cell vulnerability through synthetic lethality
por: Navare, Arti T., et al.
Publicado: (2022)

Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability
por: Thomas, Daniel, et al.
Publicado: (2023)

Modeling synthetic lethality
por: Le Meur, Nolwenn, et al.
Publicado: (2008)

Synthetic lethal therapy based on targeting the vulnerability of SWI/SNF chromatin remodeling complex‐deficient cancers
por: Sasaki, Mariko, et al.
Publicado: (2020)

Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways
por: Invrea, Federica, et al.
Publicado: (2021)

DNA repair and synthetic lethality
por: Guo, Gong-she, et al.
Publicado: (2011)

Synthetic Lethality in Ovarian Cancer
por: Chandrasekaran, Akshaya, et al.
Publicado: (2021)

PB1766: IN VITRO ACQUIRED RESISTANCE TO THE ORAL MYELOID KINASE INHIBITOR TUSPETINIB CREATES SYNTHETIC LETHAL VULNERABILITY TO VENETOCLAX
por: Sonowal, Himangshu, et al.
Publicado: (2023)

Protease Addiction and Synthetic Lethality in Cancer
por: Freije, José M. P., et al.
Publicado: (2011)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Protocol for Comprehensive Synthetic Lethality Screens
por: Romero-Moya, Damia, et al.
Publicado: (2020)

The tumor therapy landscape of synthetic lethality
por: Zhang, Biyu, et al.
Publicado: (2021)

Overview of Ferroptosis and Synthetic Lethality Strategies
por: Kinowaki, Yuko, et al.
Publicado: (2021)

Synthetic Lethality Targeting Polθ
por: Drzewiecka, Małgorzata, et al.
Publicado: (2022)

Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells
por: Jaiswal, Alok, et al.
Publicado: (2017)

An RNA Interference Lethality Screen of the Human Druggable Genome to Identify Molecular Vulnerabilities in Epithelial Ovarian Cancer
por: Sethi, Geetika, et al.
Publicado: (2012)

Synthetic Vulnerabilities in the KRAS Pathway
por: Roman, Marta, et al.
Publicado: (2022)

Development of Synthetic Lethality Anticancer Therapeutics: Miniperspective
por: Fang, Bingliang
Publicado: (2014)

Approaches to Identifying Synthetic Lethal Interactions in Cancer
por: Thompson, Jordan M., et al.
Publicado: (2015)

Synthetically Lethal Nanoparticles for Treatment of Endometrial Cancer
por: Ebeid, Kareem, et al.
Publicado: (2017)

Synthetic lethality: emerging targets and opportunities in melanoma
por: Thompson, Nicola, et al.
Publicado: (2017)

Epigenetic synthetic lethality approaches in cancer therapy
por: Yang, Haoshen, et al.
Publicado: (2019)

Synthetic Lethality through the Lens of Medicinal Chemistry
por: Myers, Samuel H., et al.
Publicado: (2020)

Breast Cancer Predisposition Genes and Synthetic Lethality
por: Neiger, Hannah E., et al.
Publicado: (2021)

Harnessing Synthetic Lethal Interactions for Personalized Medicine
por: Shieh, Grace S.
Publicado: (2022)

Rapid Inhibitor Discovery by Exploiting Synthetic Lethality
por: Muscato, Jacob D., et al.
Publicado: (2022)

Overcoming selection bias in synthetic lethality prediction
por: Seale, Colm, et al.
Publicado: (2022)

Mslar: Microbial synthetic lethal and rescue database
por: Zhu, Sen-Bin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_61hr10adcjoudvi559r4e43qi3